PL3646854T3 - Kompozycje do transfekcji mrna do komórki i ich zastosowania - Google Patents

Kompozycje do transfekcji mrna do komórki i ich zastosowania

Info

Publication number
PL3646854T3
PL3646854T3 PL18306417.9T PL18306417T PL3646854T3 PL 3646854 T3 PL3646854 T3 PL 3646854T3 PL 18306417 T PL18306417 T PL 18306417T PL 3646854 T3 PL3646854 T3 PL 3646854T3
Authority
PL
Poland
Prior art keywords
compositions
applications
cell
transfecting mrna
transfecting
Prior art date
Application number
PL18306417.9T
Other languages
English (en)
Inventor
Fabrice Stock
Valérie TOUSSAINT MOREAU
Patrick Erbacher
Original Assignee
Polyplus Transfection
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polyplus Transfection filed Critical Polyplus Transfection
Publication of PL3646854T3 publication Critical patent/PL3646854T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL18306417.9T 2018-10-30 2018-10-30 Kompozycje do transfekcji mrna do komórki i ich zastosowania PL3646854T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18306417.9A EP3646854B1 (en) 2018-10-30 2018-10-30 Compositions for transfecting mrna into a cell and their applications

Publications (1)

Publication Number Publication Date
PL3646854T3 true PL3646854T3 (pl) 2023-01-02

Family

ID=64572258

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18306417.9T PL3646854T3 (pl) 2018-10-30 2018-10-30 Kompozycje do transfekcji mrna do komórki i ich zastosowania

Country Status (13)

Country Link
US (1) US20210386841A1 (pl)
EP (1) EP3646854B1 (pl)
JP (1) JP7477504B2 (pl)
KR (1) KR20210084511A (pl)
CN (1) CN112930172B (pl)
AU (1) AU2019373387B2 (pl)
DK (1) DK3646854T3 (pl)
ES (1) ES2927532T3 (pl)
IL (1) IL282579B2 (pl)
PL (1) PL3646854T3 (pl)
PT (1) PT3646854T (pl)
SG (1) SG11202103117RA (pl)
WO (1) WO2020089342A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022006534A2 (pt) 2019-10-24 2022-07-05 Novago Therapeutics Ag Anticorpos anti-nogo-a
EP4153560A4 (en) * 2020-05-19 2024-04-24 Ramot at Tel-Aviv University Ltd. LIPID PARTICLES FOR NUCLEIC ACID DELIVERY AND CLINICAL APPLICATIONS THEREOF
WO2021245184A1 (en) 2020-06-02 2021-12-09 Neurimmune Ag HUMAN ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2)
CN117098541A (zh) 2020-11-25 2023-11-21 阿卡格拉医药公司 用于递送核酸的脂质纳米粒及相关使用方法
EP4547229A1 (en) * 2022-06-30 2025-05-07 Universiteit Gent Cationic amphiphilic compound-based nanoparticle compositions
CN119486721A (zh) * 2022-07-08 2025-02-18 宝利普拉斯生物转染公司 包含基于咪唑鎓的阳离子脂质的脂质纳米颗粒
WO2026036019A1 (en) 2024-08-09 2026-02-12 Life Technologies Corporation Method of producing a recombinant protein in hek-293 cells
WO2026147802A1 (en) 2024-12-30 2026-07-09 Life Technologies Corporation Composition, system, and method for adeno-associated virus (aav) production
WO2026162825A1 (en) 2025-02-03 2026-08-06 Sartorius Polyplus New cationic, ionizable and biodegradable compounds as transfection reagents

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627159A (en) 1994-10-27 1997-05-06 Life Technologies, Inc. Enhancement of lipid cationic transfections in the presence of serum
FR2732895B1 (fr) * 1995-04-11 1997-05-16 Pasteur Merieux Serums Vacc Utilisation d'un compose amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament
CA2350882C (en) 1998-11-12 2011-02-22 Life Technologies Corporation Transfection reagents
US20040072769A1 (en) * 2002-09-16 2004-04-15 Yin James Qinwei Methods for design and selection of short double-stranded oligonucleotides, and compounds of gene drugs
EP1844772A1 (en) * 2006-04-06 2007-10-17 Polyplus-Transfection SA Compositions for transfection of oligonucleotides active for gene silencing and their biological and therapeutical applications
EP2860255A1 (en) * 2013-10-14 2015-04-15 Technische Universität Graz Compositions comprising cationic and neutral lipids for transfecting nucleic acid molecules into eukaryotic cells
US10195280B2 (en) * 2014-07-15 2019-02-05 Life Technologies Corporation Compositions and methods for efficient delivery of molecules to cells
ES2969956T3 (es) * 2014-09-05 2024-05-23 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
SG11201803915UA (en) * 2015-11-10 2018-06-28 Childrens Research Institute Childrens National Medical Center Echinomycin formulation, method of making and method of use thereof
WO2017218891A1 (en) * 2016-06-17 2017-12-21 Life Technologies Corporation Site-specific crosslinking of antibodies
WO2018112470A1 (en) * 2016-12-16 2018-06-21 The Brigham And Women's Hospital, Inc. Co-delivery of nucleic acids for simultaneous suppression and expression of target genes

Also Published As

Publication number Publication date
CN112930172A (zh) 2021-06-08
WO2020089342A1 (en) 2020-05-07
ES2927532T3 (es) 2022-11-08
DK3646854T3 (da) 2022-09-26
SG11202103117RA (en) 2021-04-29
EP3646854B1 (en) 2022-08-03
IL282579A (en) 2021-06-30
IL282579B2 (en) 2024-11-01
JP7477504B2 (ja) 2024-05-01
AU2019373387A1 (en) 2021-04-29
EP3646854A1 (en) 2020-05-06
CA3113877A1 (en) 2020-05-07
AU2019373387B2 (en) 2025-04-17
KR20210084511A (ko) 2021-07-07
JP2022512983A (ja) 2022-02-07
PT3646854T (pt) 2022-09-27
CN112930172B (zh) 2023-12-22
US20210386841A1 (en) 2021-12-16
IL282579B1 (en) 2024-07-01

Similar Documents

Publication Publication Date Title
IL282579A (en) Mixtures for mRNA transfection into cells and their applications
IL320642B1 (en) Compositions and methods for t cell engineering
IL277673A (en) Transgenic cells and their uses
IL287874A (en) Preparations and methods for producing t cells
IL287553A (en) Modified pluripotent cells
GB202104653D0 (en) Engineered regulatory t cell
SG11202004116QA (en) T cell manufacturing compositions and methods
SG11202101778TA (en) Modified plant messenger packs and uses thereof
GB201819540D0 (en) T cell modification
IL281531A (en) Cells produce insulin
SG11202111679XA (en) Engineered cells and uses thereof
IL290398A (en) Material delivery systems and methods
GB201803079D0 (en) Cell
IL290109A (en) Cells for enhanced immune healing and their uses
SG10201913497XA (en) Biopharmaceutical compositions and related methods
IL273247A (en) New cell row and its uses
GB201915526D0 (en) Modified cell
SG11202102538RA (en) Compositions and methods for transfecting cells
GB201904971D0 (en) Cell
GB201807693D0 (en) Cell
GB201804908D0 (en) Binder compositions and uses thereof
GB201906202D0 (en) Cell
SG11202103758TA (en) Dielectric copolymer materials
GB201805918D0 (en) Cell
GB201803363D0 (en) New materials and uses thereof